PH1

PH1 is a proprietary Thailanstatin analog that functions as an anti-splicing agent, targeting spliceosomes and pre-mRNA splicing. It exhibits anti-tumor activity in preclinical xenograft and syngeneic models, particularly when utilized as a payload in Antibody-Drug Conjugates (ADCs) targeting Her2 and Trop2. PH1 stimulates intron retention and the generation of neoantigens, which in turn enhances immune responses against cancer cells, including increased tumor infiltration of neutrophils, macrophage repolarization, and the expansion of specific immune cell clones, especially in combination with checkpoint inhibitors.